Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized extension to study AC-066A401. The study will assess
safety and tolerability of ACT-385781A and Flolan (epoprostenol sodium) while providing a
means for continuing treatment after ending participation in study AC-0066A401.